TNXP: Raymond James Initiates
Raymond James analyst initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and a price target of $26
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst James Schneider initiated coverage on Intel Corp (NASDAQ: INTC ) with a Neutral rating and announced a price target of $150. 91 on Wednesday.
See how other analysts view this stock. Keefe, Bruyette & Woods analyst Damon Delmonte initiated coverage on Arrow Financial Corp (NASDAQ: AROW ) with a Market Perform rating and announced a price target of $42. 36 on Wednesday. See how other analysts view this stock.
BTIG analyst Gregory Lewis initiated coverage on Boost Run Inc (NASDAQ: BRUN ) with a Buy rating and announced a price target of $45. 26 on Wednesday. See how other analysts view this stock. Raymond James analyst Tiago Fauth initiated coverage on Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) with a Strong Buy rating and announced a price target of $26.
10 on Wednesday. See how other analysts view this stock. Roth Capital analyst Max Masucci initiated coverage on Castle Biosciences Inc (NASDAQ: CSTL ) with a Buy rating and announced a price target of $40. 12 on Wednesday.
See how other analysts view this stock. Considering buying TNXP stock? Here’s what analysts think: Photo via Shutterstock